Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 9/20 | 0.46 |
| ▸ | NMT2 | O60551 | 8/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | NPY1R | P25929 | 3/20 | 0.39 |
| ▸ | NPY4R | P50391 | 3/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909077 | 0.91 | NMT1 (0.48) | NMT1NMT2TLR2NPY5RNPY1R | |
| SCHEMBL21474404 | 0.91 | PTGS1 (0.45) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL19681467 | 0.91 | PTGS1 (0.45) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL17722904 | 0.91 | NMT1 (0.45) | NMT1NMT2TLR2NPY5RNPY1R | |
| SCHEMBL23420959 | 0.90 | FAP (0.37) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL20887736 | 0.90 | FAP (0.37) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL27421373 | 0.89 | FAP (0.36) | NMT1NMT2NPY5RNPY1RNPY4R | |
| SCHEMBL18909079 | 0.88 | NPY5R (0.39) | NMT1NMT2TLR2NPY5RNPY1R | |
| SCHEMBL20340675 | 0.88 | NMT1 (0.43) | NMT1NMT2TLR2NPY5RNPY1R | |
| SCHEMBL23256415 | 0.87 | PTGS1 (0.41) | NMT1NMT2NPY5RNPY1RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2023014863-A1 | ANTI-GLYCO-MUC4 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | NMT1 3358/4885NMT2 2928/4885TLR2 224/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | NMT1 92/4885NMT2 82/4885TLR2 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.